Al-Jussani Ghada N, Dabbagh Tamara Z, Al-Rimawi Dalia, Sughayer Maher A
Department of Pathology, Faculty of Medicine, Hashemite University, Zarqa, Jordan.
Department of Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman, Jordan.
Ann Diagn Pathol. 2021 Apr;51:151703. doi: 10.1016/j.anndiagpath.2021.151703. Epub 2021 Jan 9.
Triple negative breast cancer (TNBC) represents a small subtype of breast cancer yet it has the worst outcome. Immunotherapy using immune checkpoint inhibitors combined with chemotherapy was recently approved by the FDA raising the hope for an improved outcome. The approval was based on demonstration of a positive PD-L1 expression using the SP142 CDx assay . We aimed to study a cohort of TNBC patients in terms of prevalence of the PD-L1 expression using the approved assay and to investigate its association with clinicopathological variables. This is a single center retrospective study consisting of 49 TNBC patients who had available archived paraffin-embedded tissue blocks from the primary tumors. All blocks were stained using the SP142 CDx assay as per the manufacture's instruction. Clinicopathological data were collected from medical records. Eighteen of the 49 (36.7%) patients were found to have a score of 1% or more by the immune cell-scoring algorithm. PDL-1 expression was significantly associated with the degree of tumor infiltrating lymphocytes (TILs). No additional significant relationship was found between PD-L1 expression and any of the other investigated clinicopathological variables. Although a trend of favorable prognostic association with PD-L1 expression was noted. The overall and event free survival were significantly related to pathological response to neoadjuvant therapy. Conclusion: Our PD-L1 rate of 36.7% is close to the results of the previously reported 40.9% in the IMpassion 130 trial. There were no significant association between positive PD-L1 expression and clinicopathological variables however a trend of a favorable outcome was observed.
三阴性乳腺癌（TNBC）是乳腺癌的一种小亚型，但其预后最差。使用免疫检查点抑制剂联合化疗的免疫疗法最近已获美国食品药品监督管理局（FDA）批准，给改善预后带来了希望。该批准基于使用SP142伴随诊断检测法证明PD-L1表达呈阳性。我们旨在使用已获批的检测法研究一组TNBC患者的PD-L1表达患病率，并调查其与临床病理变量的关联。这是一项单中心回顾性研究，纳入了49例TNBC患者，这些患者有原发性肿瘤的存档石蜡包埋组织块。所有组织块均按照制造商的说明使用SP142伴随诊断检测法进行染色。临床病理数据从病历中收集。49例患者中有18例（36.7%）通过免疫细胞评分算法得出的评分为1%或更高。PDL-1表达与肿瘤浸润淋巴细胞（TILs）的程度显著相关。在PD-L1表达与任何其他研究的临床病理变量之间未发现额外的显著关系。尽管注意到PD-L1表达与预后呈有利关联的趋势。总生存期和无事件生存期与新辅助治疗的病理反应显著相关。结论：我们的PD-L1率为36.7%，接近IMpassion 130试验中先前报道的40.9%的结果。PD-L1阳性表达与临床病理变量之间无显著关联，然而观察到有预后良好的趋势。
